Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Concomitant Repevax and bivalent rLP2086 vaccine study in healthy adolescents
2010-022449-38Phase 2Completed
- Sponsor
- Pfizer
- Start
- Dec 2010
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial in meningococcal disease and bacterial meningitis comparing Concomitant Repevax + bivalent rLP2086 vaccine with Repevax alone control (2 arms). Primary endpoints: Primary immunogenicity endpoint and Repevax non-inferiority objective. Started Dec 2010; status: completed.
02
Drugs
Adacel Poliomeningococcal group B recombinant lipoprotein 2086 vaccine
03
Conditions
meningococcal diseasebacterial meningitis
Beyond the preview
Go deeper on 2010-022449-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022449-38.